Lv1
20 积分 2023-04-19 加入
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
1个月前
已完结
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma
3个月前
已关闭
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
3个月前
已完结
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma
3个月前
已完结
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
3个月前
已完结
Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy
5个月前
已完结
Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma
5个月前
已完结
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma
5个月前
已完结
Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome
5个月前
已完结
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
6个月前
已完结
皖公网安备34019202002308
